CA
SUPN icon

Cynosure Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Cynosure Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,260
Closed -$494K – 167
2018
Q2 		$494K Buy
8,260
+2,930
+55% +$152K 0.13% 105
2018
Q1 		$244K Buy
5,330
+60
+1% +$2.5K 0.06% 200
2017
Q4 		$210K Buy
+5,270
New +$208K 0.05% 219

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Cynosure Advisors's SUPN Position: Q3 2018 in Review

Cynosure Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 8,260 shares — an estimated $494K sold.

Cynosure Advisors first reported a position in SUPN in Q4 2017 and held it in 3 quarters. The position peaked at $494K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Cynosure Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cynosure Advisors sold 8,260 Supernus Pharmaceuticals shares in Q3 2018, an estimated $494K.
  • Cynosure Advisors first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Cynosure Advisors's Supernus Pharmaceuticals position peaked at $494K in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.